N
ATRA icon

Nuveen’s Atara Biotherapeutics ATRA Stock Holding History

Nuveen’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,315
Closed -$197K – 3320
2023
Q3 		$197K Buy
5,315
+2,766
+109% +$123K ﹤0.01% 3043
2023
Q2 		$103K Sell
2,549
-63,935
-96% -$3.62M ﹤0.01% 3164
2023
Q1 		$4.82M Buy
66,484
+15,490
+30% +$1.5M ﹤0.01% 1912
2022
Q4 		$4.18M Buy
50,994
+30,094
+144% +$3.14M ﹤0.01% 2014
2022
Q3 		$1.98M Buy
20,900
+43
+0.2% +$4.83K ﹤0.01% 2411
2022
Q2 		$4.06M Sell
20,857
-21,750
-51% -$3.55M ﹤0.01% 2086
2022
Q1 		$10M Sell
42,607
-3,811
-8% -$1.21M ﹤0.01% 1636
2021
Q4 		$18.3M Buy
46,418
+3,988
+9% +$1.68M 0.01% 1284
2021
Q3 		$19M Sell
42,430
-3,478
-8% -$1.25M 0.01% 1305
2021
Q2 		$17.8M Buy
45,908
+1,056
+2% +$377K 0.01% 1463
2021
Q1 		$16.1M Buy
44,852
+3,438
+8% +$1.52M 0.01% 1477
2020
Q4 		$20.3M Buy
41,414
+9,945
+32% +$4.59M 0.01% 1258
2020
Q3 		$10.2M Buy
31,469
+15,018
+91% +$5.11M ﹤0.01% 1506
2020
Q2 		$5.99M Buy
16,451
+229
+1% +$57.8K ﹤0.01% 1801
2020
Q1 		$3.45M Buy
16,222
+4,519
+39% +$1.43M ﹤0.01% 1908
2019
Q4 		$4.82M Buy
11,703
+2,702
+30% +$932K ﹤0.01% 2021
2019
Q3 		$3.18M Buy
9,001
+1,033
+13% +$385K ﹤0.01% 2186
2019
Q2 		$4.01M Buy
+7,968
New +$5.62M ﹤0.01% 2102

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen's ATRA Position: Q4 2023 in Review

Nuveen sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 5,315 shares — an estimated $197K sold.

Nuveen first reported a position in ATRA in Q2 2019 and held it in 18 quarters. The position peaked at $20.3M in Q4 2020. 89 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • Nuveen reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Nuveen sold 5,315 Atara Biotherapeutics shares in Q4 2023, an estimated $197K.
  • Nuveen first reported a position in Atara Biotherapeutics in Q2 2019 and held it in 18 quarters.
  • Nuveen's Atara Biotherapeutics position peaked at $20.3M in Q4 2020.
  • 89 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on Nuveen's 13F filing for Q4 2023, filed 14 Feb 2024.